120
Views
2
CrossRef citations to date
0
Altmetric
Anticancer Original Research Paper

Long-term physico-chemical stability of 5-fluorouracile at standardised rounded doses (SRD) in MyFuser® portable infusion pump

ORCID Icon, , , , , , , , & show all
Pages 486-491 | Received 17 Nov 2020, Accepted 16 Mar 2021, Published online: 09 Apr 2021

References

  • Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study - The Lancet [Internet]. [cited 2020 Aug 26]. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32007-0/fulltext#%20.
  • Chatelut E, White-Koning ML, Mathijssen RH, Puisset F, Baker SD, Sparreboom A. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer. 2012; 107(7):1100–6.
  • Plumridge RJ, Sewell GJ. Dose-banding of cytotoxic drugs: A new concept in cancer chemotherapy. Am J Health Syst Pharm. 2001; 58(18):1760–4.
  • Koundalijan J. Setting up a CIVAS. In The CIVAS Handbook. 1st ed. London: London Pharmaceutical Press; 1998. p. 1–5.
  • Soumoy L, Pirlot C, Decoster C, Gillet P, Hecq JD. Etude préliminaire pour l’implémentation d’un dose-banding de chimiothérapie anticancéreuse. Journal De Pharmacie De Belgique. 2015;97(3):24–35.
  • Hecq JD. Centralized intravenous additive services (CIVAS): the state of the art in 2010. Ann Pharm Fr. 2011; 69(1):30–7.
  • Pérez HP, Cueto SM, Escobar CP, Borrell GC, Albert MA, López BE, et al. Applying dose banding to the production of antineoplastic drugs: a narrative review of the literature. Farm Hosp. 2015;39(4):210–6.
  • Lien K, Cheung MC, Chan KKW. Adjusting for drug wastage in economic evaluations of new therapies for hematologic malignancies: a systematic review. J Oncol Pract. 2016; 12(4):e369–e379.
  • Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003; 3(5):330–8.
  • Milano G, Etienne MC, Cassuto-Viguier E, Renée N, Bousselet M, Guillot T, Lecompte D. Long-term stability of 5-fluorouracil and folinic acid admixtures. Eur J Cancer. 1992;29A(1):129–32.
  • Stiles ML, Allen LV, Tu YH. Stability of fluorouracil administered through four portable infusion pumps. Am J Hosp Pharm. 1989; 46(10):2036–40.
  • Galanti L, Lebitasy MP, Hecq J-D, Cadrobbi J, Vanbeckbergen D, Jamart J. Long-term stability of 5-fluorouracil in 0.9% sodium chloride after freezing, microwave thawing, and refrigeration. Can J Hosp Pharm. 2009;62(1):34–8.
  • Martel P, Petit I, Pinguet F, Poujol S, Astre C, Fabbro M. Long-term stability of 5-fluorouracil stored in PVC bags and in ambulatory pump reservoirs. J Pharm Biomed Anal. 1996; 14(4):395–9.
  • Barberi-Heyob M, Watelet M, Merlin JL, Bleger C, Schroeder B. [Stability of 5-fluorouracil solutions according to different parameters]. Bull Cancer. 1995; 82(12):1025–31.
  • Reinhardt H, Trittler R, Eggleton AG, Wöhrl S, Epting T, Buck M, Kaiser S, Jonas D, Duyster J, Jung M, et al. Paving the way for dose banding of chemotherapy: an analytical approach. J Natl Compr Canc Netw. 2017;15(4):484–93.
  • Abraham J. International Conference on Harmonisation (ICH) of technical requirements for registration of pharmaceuticals for human use. In: Tietje C, Brouder A, éditeurs. Handbook of transnational economic governance regimes [Internet]. Brill| Nijhoff; 2010 [cité 16 mars 2020]. Disponible sur: https://brill.com/view/book/edcoll/9789004181564/Bej.9789004163300.i-1081_085.xml
  • Lahlou A, Blanchet B, Carvalho M, Paul M, Astier A. Mechanically-induced aggregation of the monoclonal antibody cetuximab. Ann Pharm Fr. 2009; 67(5):340–52.
  • Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs-A review. J Pharm Anal. 2014; 4(3):159–65.
  • Pinguet F, Favre G, Canal P, Pujol A, Soula G. Stabilité des solutions de 5-fluoro-uracile à la chaleur et à la lumière. Journal de Pharmacie Clinique. 1990;9:155–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.